Denovo In-Licenses Lundbeck’s Idalopirdine for Alzheimer’s Disease and Other Indications

Shots:

Denovo has licensed the global rights for idalopirdine including all rights to develop, manufacture and commercialize idalopirdine for all indications. Lundbeck gets an option to reacquire idalopirdine.
If Lundbeck exercise the option, both the companies will share rights of the product in China and if not, Denovo will retain all global rights to the product
Idalopirdine (DB109) is an oral antagonist of the serotonin (5-HT6) receptor and is hypothesized to be involved in AD, schizophrenia, and other indications. The therapy is currently being evaluated in multiple studies encompassing 2500+ subjects

Click here to read full press release/ article | Ref: PRNewswire | Image: PR Newswire